Calidi Biotherapeutics, Inc. (CLDI) has announced a strategic partnership with Avance Clinical to launch a first-in-human clinical trial for its investigational candidate, CLD-401. This genetically modified vaccinia virus, aimed at treating non-small cell lung cancer and other high-need tumor types, has propelled CLDI shares up 3.65% to $0.30 in pre-market trading. The company plans to file for Investigational New Drug (IND) status with the FDA in 2026, indicating a long-term commitment to advancing its pipeline.

The significance of this partnership lies in Calidi’s focus on a novel therapeutic approach using its proprietary Redtail platform, which could address critical gaps in cancer treatment. The upcoming Phase I trial will assess the safety and efficacy of CLD-401 in patients with solid tumors who have limited options left, potentially positioning Calidi as a player in the oncology space.

For market professionals, the key takeaway is that CLDI’s recent developments may enhance investor interest, particularly as the company navigates the complexities of clinical trials and regulatory pathways, which can significantly impact stock performance in the biotech sector.

Source: nasdaq.com